Voxmind | $735,203 | (Jun 2, 2026)
Invertix | $1,977,831 | (Jun 2, 2026)
XCENA | $135,000,000 | (Jun 2, 2026)
Certified by Founder
Lodge
KROMATID®
start up
United States
- Longmont, Colorado
- 21/08/2025
- Series C
- $8,000,000
Revolutionizing gene editing analysis for precision medicine and cutting-edge research.
For cell and gene therapy researchers, biotech and pharma companies, and regulatory professionals, KROMATID’s KROMASURE Platform is the genomic characterization solution that provides high-confidence, single-cell insights into chromosomal integrity, structural variants, and transgene mapping.
Unlike traditional sequencing methods, our technology directly visualizes up to thousands of single cells at a time, offering scalable, actionable data with unprecedented clarity, helping you confidently advance research and meet FDA regulatory requirements.
Visit our website to learn how we can support your research.
- Industry Biotechnology Research
- Website https://kromatid.com/
- LinkedIn https://www.linkedin.com/company/kromatid/
Inherent | $50,000,000 | (Jun 2, 2026)
Gray Swan | $40,000,000 | (Jun 2, 2026)
Handshake(UK) | $3,200,000 | (Jun 2, 2026)
Sekai(US) | $26,000,000 | (Jun 2, 2026)
Human Archive (YC W26) | $8,200,000 | (Jun 2, 2026)
Perceptic | $12,000,000 | (Jun 2, 2026)
SpeedLabs | $6,500,000 | (Jun 2, 2026)
MokN | $15,000,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)